pp-016 Injection, pre-filled syringe 0.3 g/2 ml
Dossier type
CTD
Dossier status
Under development
Country of origin
China
Comments
For hyperlipidemia and homozygous familial hypercholesterolemia. Phase 3. Targets ANGPTL3. Cardiovascular lipid-modifying agent designed to lower LDL-C in severe dyslipidemia. Same class as evinacumab.
Manufacturer #17216
Global developer of innovative drugs in oncology, metabolic, autoimmune, and cardiovascular diseases, with 14 in-house products and multiple partnerships. Over 5,000 R&D staff across global centers and strong IP, clinical pipeline, and high-standard manufacturing.
Manufacturer usually replies in 41 days